

UNITED STATE EPARTMENT OF COMMERCE **United States Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS (Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR		A	TTORNEY DOCKET NO.
09/436,184	11/08/99	WANDS	• •	J	04930/03200
			—	EXAMINER	
INGRID A.	REATTIE	HM12/1019		CANELL	A 1/2
		ERRIS, GLOVSKY AN	D [ART UNIT	PAPER NUMBER
ONE FINANC	IAL CENTER			, , , = , =	. 11
BOSTON MA	02111			1642	
				DATE MAILED:	

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office Action Summary

Application No. 09/436,184

Applicant(s)

Wands et al

Examiner

Karen Canella

Art Unit **1642**

The MAILING DATE of this communication app	ears on the cover sheet with the correspondence address
Period for Reply	A CET TO EVENETO (1) MONTHYON EDOM
A SHORTENED STATUTORY PERIOD FOR REPLY IS THE MAILING DATE OF THIS COMMUNICATION.	
 Extensions of time may be available under the provisions of 37 CF after SIX (6) MONTHS from the mailing date of this communical. If the period for reply specified above is less than thirty (30) days, 	ation.
be considered timely.	eriod will apply and will expire SIX (6) MONTHS from the mailing date of this
communication.	
 Failure to reply within the set or extended period for reply will, by si Any reply received by the Office later than three months after the rearned patent term adjustment. See 37 CFR 1.704(b). 	tatute, cause the application to become ABANDONED (35 U.S.C. § 133). mailing date of this communication, even if timely filed, may reduce any
Status	
1) Responsive to communication(s) filed on	
2a) ☑ This action is FINAL. 2b) ☐ This	action is non-final.
3) Since this application is in condition for allowand closed in accordance with the practice under	ce except for formal matters, prosecution as to the merits is Ex parte Quayl@35 C.D. 11; 453 O.G. 213.
Disposition of Claims	
4) 🗓 Claim(s) <u>10, 13-15, and 39-68</u>	is/are pending in the applica
4a) Of the above, claim(s)	is/are withdrawn from considera
5)	is/are allowed.
6) ☑ Claim(s) <u>10, 13-15, and 39-68</u>	is/are rejected.
7)	is/are objected to.
8)	are subject to restriction and/or election requirem
Application Papers	
9) The specification is objected to by the Examiner.	
10) The drawing(s) filed on	is/are objected to by the Examiner.
11) The proposed drawing correction filed on	is: a∏ approved b) ☐ disapproved.
12) The oath or declaration is objected to by the Example 12.	
Priority under 35 U.S.C. § 119	
13) Acknowledgement is made of a claim for foreign	priority under 35 U.S.C. § 119(a)-(d).
a) ☐ All b) ☐ Some* c) ☐None of:	
1. Certified copies of the priority documents h	
2. Certified copies of the priority documents have	
 Copies of the certified copies of the priority application from the International Bur *See the attached detailed Office action for a list of 	
14) ☐ Acknowledgement is made of a claim for domest	•
Attachment(s) 15) Notice of References Cited (PTO-892)	18) Interview Summary (PTO-413) Paper No(s).
15) Notice of References Cited (PTO-092) 16) Notice of Draftsperson's Patent Drawing Review (PTO-948)	19) Notice of Informal Patent Application (PTO-152)
17) Information Disclosure Statement(s) (PTO-1449) Paper No(s).	

Page 2

Application/Control Number: 09/436,184

Art Unit: 1642

Response to Amendment

- 1. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office Action.
- 2. Claim 10 is amended. Claims 1-9, 11, 12 and 16-38 have been canceled. Claims 39-68 have been added. Claims 10, 13-15 and 39-68 are pending and under consideration.

Claim Rejections Withdrawn

3. The rejection of claims 10, 13 and 14 under 35 U.S.C. 102(e) as being anticipated by Radosevich (USP 6,166,176), is withdrawn.

Claim Rejections Maintained

4. The rejection of claims 10 and 13-15 under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for a method for inhibiting growth of a mammalian tumor cell in culture or a method for inhibiting a mammalian tumor cell line grown in culture, said methods comprising the administration of a HAAH antisense nucleic acid consisting of the full length antisense HAAH cDNA as well as antisense DNA corresponding to exon 1 of the HAAH gene, does not reasonably provide enablement for a method for inhibiting tumor growth in a mammal comprising the administration of a HAAH antisense nucleic acid, or the antisense nucleic acid to the 5' AAH regulatory sequence, is maintained for reasons of record. The rejection of newly added claims 39-68 is made for the same reasons of record. Applicant has provided the Declaration of Jack R. Wands to substantiate claims to the antisense nucleic directed to the 5' regulatory sequence of the AAH gene in a method for inhibiting tumor growth in a mammal. The declaration states that sequences of exemplary oligonucleotides from said 5' regulatory region consist of SEQ ID NO:10 through SEQ ID NO:13. However, the instant specification puts forth the polypeptide encoded by the AAH gene and the cDNA encoding said gene without any

Application/Control Number: 09/436,184 Page 3

Art Unit: 1642

برار

disclosures of the specific promoter or other regulatory region 5' to the AAH gene. Further, the Sequence Listing of the instant specification does not contain any sequence above SEQ ID NO:7.

Conclusion

5. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Karen Canella whose telephone number is (703) 308-8362. The examiner can normally be reached on Monday through Friday from 8:30 am to 6:00 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa, can be reached on (703) 308-3995. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Karen A. Canella, Ph.D.

Patent Examiner, Group 1642

October 8, 2001

ANTI ONY C. CAPUTA
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1900